Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $102.13 USD
Change Today 0.00 / 0.00%
Volume 0.0
MKGAF On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MKGAF) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - $117.55
52 Week Low
08/6/14 - $85.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK KGAA (MKGAF)

Related News

No related news articles were found.

merck kgaa (MKGAF) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MKGAF) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

39,842 Employees
Last Reported Date: 05/19/15
Founded in 1668

merck kgaa (MKGAF) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa (MKGAF) Key Developments

Merck KGaA to Invest USD 13.280 million in Rio De Janeiro Facility

Merck KGaA has announced a BRL 42 million (USD 13.280 million) investment to extend the Jacarepagua plant, in the Brazilian state of Rio de Janeiro. Merck plans to expand its production area by 30% from 4,900 square metres to 6,500 square metres. Merck targets production of 3.3 billion pills annually by 2018, up 80% on current capacity. Merck KGaA's extension plans are aimed at facilitating the development and manufacturing of eight biological drugs that are produced in co-operation with its Brazilian partner Bionovis. Additionally, Merck seeks to consolidate its position in other Latin American markets, notably Ecuador, Peru and Bolivia in the first phase, with exports set to grow by 30%. Merck also plans to enter markets in Central America, Argentina and Colombia.

Merck KGaA Receives CE Mark Approval for Gavi and Geri Fertility Technologies

Merck KGaA has received CE mark approval for the two new advanced fertility technologies Gavi and Geri, allowing to market the technologies in the European Union. Recently, Merck signed a global collaboration agreement with Genea Biomedx that manufactures both products. The agreement provided Merck global marketing and commercialization rights to Genea's product portfolio.

Merck KGaA, Illumina Inc. and Genea Limited Announce Formation of Global Fertility Alliance

Merck KGaA announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between the biopharmaceutical business of Merck, Illumina Inc. and Genea Limited. The alliance aims to improve the consistency in ART worldwide and addresses the need for more standardization of fertility processes within the ART laboratory. The three companies will launch their initiative at the 31st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lisbon, Portugal, on 13 June 2015. This is another important step for the biopharmaceuticals business of Merck, KGaA, towards establishing global standards in the growing market of fertility technologies and the ultimate goal of helping families to have a baby. With the establishment of the alliance, the biopharmaceuticals business of Merck, KGaA, Illumina and Genea emphasize their desire to help improve fertility outcomes by contributing to the standardization of technologies and protocols in ART labs. Currently, variation in practices and techniques can lead to inconsistent results and outcomes. Recognizing the importance of innovation in ART technologies the alliance aims to enhance progress and innovation in three ways: Firstly, the founding members aim to foster integration of multiple, leading fertility technologies. Secondly, building on this, the alliance will aim to collaborate with leading health care professionals and medical societies to develop global standards. And finally, as technologies in the fertility space are rapidly advancing, the alliance will also develop educational resources for health care professionals worldwide. These efforts will include training curricula and workshops as well as access to model labs, symposia and events at medical meetings.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKGAF:US $102.13 USD 0.00

MKGAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akzo Nobel NV €65.21 EUR -0.30
Johnson Matthey PLC 2,915 GBp +24.00
Seiko Epson Corp ¥2,193 JPY -19.00
Solvay SA €121.75 EUR +0.55
Yara International ASA 406.60 NOK -2.80
View Industry Companies

Industry Analysis


Industry Average

Valuation MKGAF Industry Range
Price/Earnings 37.1x
Price/Sales 3.5x
Price/Book 3.0x
Price/Cash Flow 11.0x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at